IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024

    Date:

    IGC Pharma (NYSEMKT:IGC) just reported results for the fourth quarter of 2024.

    • IGC Pharma reported earnings per share of -4 cents. This met the analyst estimate for EPS of -4 cents.
    • The company reported revenue of $295,000.
    • This was 55.26% better than the analyst estimate for revenue of $190,000.

    InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

    Go Source

    Chart

    SignUp For Breaking Alerts

    New Graphic

    We respect your email privacy

    Share post:

    Popular

    More like this
    Related

    Goods Inflation Threatens a Return: Nov. 27, 2024

    A one-two punch of hawkish trade rhetoric from President-elect...

    Coding Order Functions with the IBrokers Package

    Your Privacy When you visit any website it may use...

    IPO Trends and Forecasts in an Election Year

    Michael Normyle – Nasdaq’s US Economist joins IBKR’s Jeff Praissman...

    Lots to Digest, Data Before Turkey

    Your Privacy When you visit any website it may use...